Phase II Trial of RC1416 Injection in Asthma

Exclusion Criteria

• •Individuals with a known history of allergy to the investigational product or its excipients.
• •Clinically diagnosed with chronic obstructive pulmonary disease (COPD) or other lung diseases that may impair lung function .
• •Experienced a severe asthma exacerbation event from within 1 month prior to screening until before dosing.
• •Used systemic corticosteroids within 1 month prior to screening.
• •Had a pulmonary or other site infection requiring intravenous antibiotics, antifungals, or antivirals from within 1 month prior to screening until before dosing.
• •Used traditional Chinese medicine with anti-asthmatic effects within 1 month prior to screening.
• •Underwent major surgery within 8 weeks prior to screening or plans to undergo major surgery during the study period.
• •With a history of malignancy within the past 5 years .
• •Active or incompletely treated tuberculosis
• •Used biologic/systemic immunosuppressant/immunomodulators within 12 weeks or 5 half-lives prior to screening.
• •Diagnosed active parasitic infection; suspected parasitic infection or high risk of infection.
• •Abnormal 12-lead electrocardiogram (ECG) at screening. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial